Exemestane
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| ER-positive early breast cancer — adjuvant (sequential after tamoxifen) | Postmenopausal women who have completed 2–3 years of tamoxifen | Monotherapy; switch to complete 5 years total endocrine therapy | FDA Approved |
| Advanced breast cancer — post-tamoxifen progression | Postmenopausal women with disease progression on tamoxifen | Monotherapy | FDA Approved |
Exemestane occupies a distinct position among aromatase inhibitors as the only steroidal, irreversible aromatase inactivator in clinical use. In the landmark Intergroup Exemestane Study (IES), switching from tamoxifen to exemestane after 2–3 years significantly improved disease-free survival compared with completing 5 years of tamoxifen (HR 0.76, p=0.0001 at 55.7 months), with benefits translating into a modest overall survival improvement at long-term follow-up. For advanced disease progressing on tamoxifen, exemestane offers an effective second-line endocrine option with favourable tolerability compared with megestrol acetate.
Breast cancer risk reduction in high-risk postmenopausal women (Evidence: High). In the MAP.3 trial (N Engl J Med 2011), exemestane 25 mg daily for 5 years reduced invasive breast cancer by 65% compared with placebo (HR 0.35, 95% CI 0.18–0.70; p=0.002) at a median follow-up of 35 months. No increase in serious adverse events, fractures, or cardiovascular events was observed.
ER-positive early breast cancer in premenopausal women with ovarian suppression (Evidence: High). The TEXT/SOFT combined analysis demonstrated that exemestane plus ovarian suppression significantly improved disease-free survival vs tamoxifen plus ovarian suppression (HR 0.72, p<0.001). This use is guideline-supported by ASCO and NCCN.
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| ER+ early breast cancer — sequential switch after 2–3 years tamoxifen | 25 mg once daily | 25 mg once daily | 25 mg/day | Continue to complete a total of 5 years adjuvant endocrine therapy Must be taken after a meal for optimal absorption |
| Advanced breast cancer — after tamoxifen progression | 25 mg once daily | 25 mg once daily | 25 mg/day | Continue until disease progression Food increases bioavailability by ~59% |
| Breast cancer risk reduction — high-risk postmenopausal women (off-label) | 25 mg once daily | 25 mg once daily | 25 mg/day | 5-year course per MAP.3 protocol Not FDA-approved for prevention |
| ER+ breast cancer in premenopausal women with ovarian suppression (off-label) | 25 mg once daily | 25 mg once daily | 25 mg/day | Combined with GnRH agonist, oophorectomy, or ovarian irradiation for 5 years Per TEXT/SOFT protocol; guideline-supported |
| Concomitant strong CYP3A4 inducer (rifampicin, phenytoin, carbamazepine) | 50 mg once daily | 50 mg once daily | 50 mg/day | Dose increase required; CYP3A4 induction reduces exemestane AUC by ~54% FDA PI Section 2.2 |
Special Populations
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Renal impairment (including severe, CrCl <35 mL/min) | 25 mg once daily | 25 mg once daily | 25 mg/day | AUC ~3× higher but no dose adjustment required; well tolerated at repeated doses up to 200 mg/day (FDA PI) |
| Hepatic impairment (moderate-severe; Child-Pugh B/C) | 25 mg once daily | 25 mg once daily | 25 mg/day | AUC ~3× higher but no dose adjustment required based on tolerability data (FDA PI) |
| Elderly | 25 mg once daily | 25 mg once daily | 25 mg/day | No age-related PK differences observed (age range 43–68 in PK studies) (FDA PI) |
Unlike anastrozole and letrozole, exemestane absorption is significantly affected by food. A high-fat meal increases the AUC by 59% and Cmax by 39% compared with fasting. The FDA label specifies administration after a meal for all indications. Patients should be counselled to take their tablet consistently after breakfast or another substantial meal to ensure reliable drug exposure. This is the most important practical prescribing distinction from the non-steroidal aromatase inhibitors.
Pharmacology
Mechanism of Action
Exemestane is structurally related to the natural aromatase substrate androstenedione. It functions as a false substrate that is processed by the aromatase enzyme (CYP19A1) to a reactive intermediate which binds covalently and irreversibly to the active site, permanently inactivating the enzyme. This mechanism is termed “suicide inhibition” and distinguishes exemestane from the non-steroidal, reversible inhibitors anastrozole and letrozole. Because inhibition is irreversible, new aromatase protein must be synthesized before estrogen production can resume, resulting in prolonged estradiol suppression even after drug clearance. At the 25 mg daily dose, exemestane achieves 85–95% suppression of plasma estrogens and reduces whole-body aromatization by approximately 98%. Importantly, exemestane has no meaningful effect on adrenal corticosteroid or aldosterone synthesis, so no steroid replacement is required. A notable pharmacological feature is that the 17-dihydrometabolite of exemestane binds the androgen receptor with approximately 100 times the affinity of the parent compound, conferring mild androgenic activity that may partially protect against bone loss.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~42% absorbed; Tmax ~1.2 h (cancer patients), ~2.9 h (healthy); high-fat meal increases AUC by 59% | Must be taken after a meal; faster absorption in patients with breast cancer than in healthy volunteers |
| Distribution | 90% plasma protein bound (albumin, α1-acid glycoprotein); extensively distributed; negligible blood cell distribution | High protein binding; distribution independent of concentration |
| Metabolism | Extensive hepatic; CYP3A4 (oxidation of position 6 methylene) + aldoketoreductases (17-keto reduction); <10% circulates unchanged; metabolites inactive or less potent | Does not inhibit major CYP isoenzymes; susceptible to CYP3A4 inducers (dose increase to 50 mg required) |
| Elimination | t½ ~24 h; 42% urine, 42% feces; <1% excreted unchanged in urine | Shorter half-life than non-steroidal AIs but irreversible binding compensates; once-daily dosing sufficient |
Side Effects
Side effect data below are primarily from the IES study (adjuvant setting, N=2,252 exemestane vs N=2,280 tamoxifen) unless otherwise stated. All rates represent incidence during treatment or within one month of treatment completion.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hot flushes | 21.2% | Most common effect; similar to tamoxifen (19.9%); reflects estrogen deprivation |
| Fatigue | 16.1% | Similar to tamoxifen (14.7%); usually mild to moderate |
| Arthralgia | 14.6% | Significantly higher than tamoxifen (8.6%); characteristic AI class effect |
| Headache | 13.1% | Higher than tamoxifen (10.8%); generally self-limiting |
| Insomnia | 12.4% | Higher than tamoxifen (8.9%); often co-occurs with hot flushes and mood changes |
| Increased sweating | 11.8% | Similar to tamoxifen (10.4%); vasomotor symptom cluster |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypertension | 9.8% | Similar to tamoxifen (8.4%); monitor BP at each visit |
| Dizziness | 9.7% | Slightly higher than tamoxifen (8.4%); advise caution with driving |
| Pain in limb | 9.0% | Higher than tamoxifen (6.4%); part of musculoskeletal syndrome |
| Back pain | 8.6% | Similar to tamoxifen (7.2%) |
| Nausea | 8.5% | Similar to tamoxifen (8.7%); usually mild; taking after a meal may help |
| Depression | 6.2% | Similar to tamoxifen (5.6%); screen regularly with validated tool |
| Osteoarthritis | 5.9% | Higher than tamoxifen (4.5%); AI-related musculoskeletal effect |
| Visual disturbances | 5.0% | Higher than tamoxifen (3.8%); ophthalmology referral if persistent |
| Osteoporosis | 4.6% | Higher than tamoxifen (2.8%); DEXA monitoring essential |
| Diarrhea | 4.2% | Higher than tamoxifen (2.2%); usually self-limiting |
| Clinical fractures | 4.2% | Higher than tamoxifen (3.1%); ensure calcium/vitamin D supplementation |
| Paresthesia | 2.6% | Higher than tamoxifen (0.9%); includes carpal tunnel syndrome (2.4% vs 0.2%) |
| Cardiac ischemic events | 1.6% | Higher than tamoxifen (0.6%); includes MI, angina, myocardial ischemia |
| Thromboembolism | 0.9% | Lower than tamoxifen (2.0%); a key safety advantage of exemestane |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Cardiac ischemic events (MI, angina) | 1.6% | During treatment | Cardiovascular risk assessment before initiation; 6 deaths from stroke and 5 from cardiac failure on exemestane arm in IES |
| Clinical fractures | 4.2% | Throughout treatment | Baseline DEXA; calcium/vitamin D; consider bisphosphonate if T-score ≤ −2.0 |
| Hepatitis (including cholestatic) | Very rare (post-marketing) | Variable | Monitor LFTs if symptoms arise; discontinue if hepatitis confirmed |
| Hypersensitivity reactions | Very rare (post-marketing) | Any time | Discontinue permanently; contraindicated on rechallenge |
| Acute generalized exanthematous pustulosis | Very rare (post-marketing) | Days to weeks | Immediate discontinuation; dermatology referral |
| Severe lymphocytopenia (CTC grade 3–4) | ~20% in advanced disease (89% had pre-existing lymphopenia) | During treatment | Monitor CBC; no increase in viral or opportunistic infections observed; 40% recovered during treatment |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Musculoskeletal symptoms | Leading cause in adjuvant setting | Arthralgia, pain in limb, back pain; may respond to AI switch |
| Hot flushes | Common contributor | Similar discontinuation rate to tamoxifen arm |
| Study 027 (vs placebo) | 12.3% exemestane vs 4.1% placebo | Higher rate reflects true drug-attributable AE burden without tamoxifen comparator effects |
Arthralgia and musculoskeletal pain are the most clinically significant tolerability concerns with all aromatase inhibitors, including exemestane. Exemestane has a theoretical advantage in bone health due to its mild androgenic metabolite, but clinical fracture rates (4.2%) remain higher than tamoxifen (3.1%). In patients intolerant of a non-steroidal AI (anastrozole or letrozole), switching to exemestane may be effective — approximately one-third of patients intolerant of one AI can tolerate another, and the steroidal vs non-steroidal distinction may be clinically relevant. Regular exercise, physiotherapy, and short-term NSAID use are reasonable supportive strategies.
Drug Interactions
Exemestane is metabolised primarily by CYP3A4 and aldoketoreductases. Notably, exemestane does not inhibit any major CYP isoenzymes (CYP1A2, 2C9, 2D6, 2E1, 3A4) and therefore has very low potential to affect other drugs. However, exemestane is susceptible to CYP3A4 induction, which is the most clinically important interaction requiring a dose adjustment.
Monitoring
-
Bone Mineral Density (DEXA)
Baseline, then every 1–2 years
Routine The IES bone substudy showed lumbar spine BMD decreased by 3.14% and femoral neck by 4.15% over 24 months with exemestane (vs −0.18% and −0.33% with tamoxifen). Women with osteoporosis or at risk should have formal DEXA at treatment commencement. Co-prescribe calcium (1,000–1,200 mg/day) and vitamin D. -
Vitamin D Level (25-OH)
Before starting treatment
Routine The FDA PI specifically recommends routine 25-hydroxy vitamin D assessment prior to aromatase inhibitor treatment due to the high prevalence of deficiency in women with early breast cancer. Supplement if deficient. -
Lipid Panel
Baseline, then annually
Routine Study 027 showed HDL cholesterol decreased by 6–9% with exemestane and an 18% increase in homocysteine was observed (vs 12% with placebo). Monitor and manage per cardiovascular risk guidelines. -
Cardiovascular Risk
Baseline assessment
Routine Cardiac ischemic events occurred in 1.6% of IES patients on exemestane vs 0.6% on tamoxifen. Assess cardiovascular risk factors before initiation; note that tamoxifen’s cardioprotective effects are lost when switching. -
Musculoskeletal Symptoms
Each clinic visit
Routine Actively inquire about joint pain, stiffness, and functional impairment. Arthralgia was 14.6% with exemestane vs 8.6% with tamoxifen. Early management improves adherence. -
Liver Function
If symptoms arise
Trigger-based Treatment-emergent bilirubin elevations occurred in 5.3% (vs 0.8% tamoxifen); alkaline phosphatase elevations in 15% (vs 2.6%). Post-marketing hepatitis reported. Check LFTs for jaundice, malaise, or right upper quadrant pain. -
Blood Pressure
Each clinic visit
Routine Hypertension occurred in 9.8% of IES patients (vs 8.4% tamoxifen). Monitor and treat per guidelines. -
Pregnancy Status
Within 7 days of initiation
Trigger-based Pregnancy test recommended within 7 days before starting (FDA PI Section 8.3). Effective contraception during treatment and for 1 month after the last dose.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to exemestane or any excipient (FDA PI Section 4).
- Pregnancy. Exemestane can cause fetal harm based on animal data and mechanism of action. Caused abortions and embryo-fetal toxicity in rats and rabbits (FDA PI Section 8.1).
Relative Contraindications (Specialist Input Recommended)
- Pre-existing severe osteoporosis (T-score < −2.5 or prior fragility fractures). DEXA showed lumbar spine BMD decrease of 3.14% and femoral neck decrease of 4.15% over 24 months. If exemestane is still required, co-prescribe bisphosphonate with close DEXA follow-up.
- Pre-existing cardiovascular disease. Cardiac ischemic events were 1.6% with exemestane vs 0.6% with tamoxifen in the IES. Document risk-benefit discussion.
Use with Caution
- Premenopausal women. Exemestane is not indicated for premenopausal breast cancer unless combined with ovarian suppression (FDA PI Section 5.5). Without adequate ovarian suppression, aromatase inhibition is insufficient and compensatory gonadotropin rise may paradoxically stimulate ovarian function.
- Vitamin D deficiency. The FDA label specifically recommends assessment and supplementation before starting any aromatase inhibitor (Section 5.2).
- Lactation. Exemestane was detected in rat milk at concentrations equivalent to plasma. Advise against breastfeeding during treatment and for 1 month after the last dose (FDA PI Section 8.2).
- Concomitant strong CYP3A4 inducers. Dose increase to 50 mg daily required to maintain therapeutic exposure (FDA PI Section 2.2).
Based on findings from animal studies and its mechanism of action, exemestane can cause fetal harm when administered to a pregnant woman. In rats and rabbits, exemestane caused abortions, embryo-fetal toxicity, prolonged gestation, and abnormal or difficult labour. Pregnancy testing is recommended within 7 days prior to initiation. Advise females of reproductive potential to use effective contraception during treatment and for 1 month after the last dose (FDA PI Sections 5.6, 8.1, 8.3).
Reductions in bone mineral density over time are observed with exemestane use. During adjuvant treatment, women with osteoporosis or at risk of osteoporosis should have bone densitometry at treatment commencement and be monitored appropriately. The IES bone substudy demonstrated clinically significant BMD decreases at the lumbar spine and femoral neck over 24 months (FDA PI Section 5.1).
Patient Counselling
Purpose of Therapy
Exemestane works by permanently blocking the enzyme that produces estrogen in postmenopausal women. This deprives hormone-sensitive breast cancer cells of the estrogen they need to grow. In the adjuvant setting, it is typically prescribed after 2–3 years of tamoxifen to complete a total of 5 years of hormonal therapy, an approach that has been shown to reduce cancer recurrence more effectively than continuing tamoxifen alone.
How to Take
Take one 25 mg tablet by mouth once daily, after a meal. The meal is essential because it significantly increases drug absorption. Taking the tablet with a meal boosts the amount of drug reaching the bloodstream by about 60% compared with taking it on an empty stomach. Choose a daily meal (ideally breakfast) and take the tablet consistently at the same time each day. If a dose is missed, take it as soon as remembered after a meal; if it is close to the next dose, skip the missed dose. Do not double up.
Sources
- AROMASIN (exemestane) Tablets. Full Prescribing Information. Pfizer Inc. Revised 05/2018. FDA Label Primary regulatory source for all dosing, pharmacokinetics, adverse reaction incidence rates, contraindications, and drug interaction data used in this monograph.
- Exemestane Tablets. DailyMed / National Library of Medicine (revised 02/2025). DailyMed Entry NLM-hosted prescribing information supporting cross-reference of current safety and PK data.
- Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081–1092. DOI Landmark IES initial results demonstrating 32% risk reduction in disease-free survival events with sequential switch to exemestane.
- Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559–570. DOI IES update at 55.7-month median follow-up confirming persistent disease-free survival benefit and emerging overall survival improvement.
- Bliss JM, Kilburn LS, Coleman RE, et al. Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J Clin Oncol. 2012;30(7):709–717. DOI IES 91-month analysis confirming 18% DFS and 14% OS improvements; source for mature safety data.
- Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–2391. DOI MAP.3 trial demonstrating 65% reduction in invasive breast cancer with exemestane vs placebo in high-risk postmenopausal women.
- Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–118. DOI Combined TEXT/SOFT analysis establishing exemestane plus ovarian suppression as superior to tamoxifen plus ovarian suppression in premenopausal women.
- Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–438. DOI ASCO guideline positioning aromatase inhibitors (including exemestane) as preferred initial or sequential adjuvant endocrine therapy.
- Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(33):3152–3165. DOI ASCO guideline recommending exemestane as a chemoprevention option for high-risk postmenopausal women.
- Di Salle E, Ornati G, Paridaens R, et al. Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1992;43(1–3):137–143. DOI Foundational characterisation of exemestane as an irreversible, mechanism-based aromatase inactivator.
- Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 — a randomized controlled phase III trial. J Clin Oncol. 2013;31(11):1398–1404. DOI Head-to-head comparison demonstrating similar efficacy and safety between exemestane and anastrozole as upfront adjuvant therapy.
- Coleman RE, Banks LM, Girgis SI, et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat. 2010;124(1):153–161. DOI IES bone substudy demonstrating BMD changes with exemestane and reversal after treatment cessation.